No Data
No Data
Investing in Blueprint Medicines (NASDAQ:BPMC) a Year Ago Would Have Delivered You a 74% Gain
Stifel Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $155
Stifel analyst Bradley Canino maintains $Blueprint Medicines(BPMC.US)$ with a buy rating, and maintains the target price at $155.According to TipRanks data, the analyst has a success rate of 45.3%
Blueprint Announces the Hiring of Industry Veteran John Smelter to Medical Outpatient Team
Blueprint Medicines to Present at Upcoming Investor Conferences
Blueprint Medicines Corporation's (NASDAQ:BPMC) Business Is Yet to Catch Up With Its Share Price
Blueprint Prep's Annual $20,000 Medical School Scholarship Now Open for Submissions